# Capillary Olanzapine Sampling Method validatiOn Study

Published: 31-07-2024 Last updated: 22-02-2025

Clinical validation of capillary microsampling with finger pricks for olanzapine. The validation method is performed in accordance with the EM guideline. In this process, the analytical methods are assessed for selectivity, carry-over, lower limit...

Ethical review Approved WMO

**Status** Pending

**Health condition type** Psychiatric disorders NEC **Study type** Observational invasive

# **Summary**

#### ID

**NL-OMON56914** 

#### Source

**ToetsingOnline** 

**Brief title** COSMOS

#### **Condition**

Psychiatric disorders NEC

#### **Synonym**

Concentration of olanzapine in blood

#### Research involving

Human

## **Sponsors and support**

Primary sponsor: Maasstadziekenhuis

Source(s) of monetary or material Support: Onderzoeksgelden MaasstadLab

#### Intervention

**Keyword:** Capillary sampling, Olanzapine, Validation, Venepuncture

#### **Outcome measures**

#### **Primary outcome**

Comparison of capillary microsampling to venepunctures to clinically validate capillary microsampling of olanzapine.

#### **Secondary outcome**

To obtain patient\*s perspectives on the finger prick capillary microsampling compared to the standard method by venepuncture.

# **Study description**

#### **Background summary**

To ensure adequate exposure to drugs, blood concentration measurements can be used to optimize drug doses, a practice known as therapeutic drug monitoring (TDM). Applying TDM for antipsychotic drug users is important to gain insight into the relationship between drug concentration, efficacy, and toxicity. Venous blood sampling is currently the standard method used for TDM. However, this method is quite invasive and can cause psychological distress in patients with pre-existing fear of injections. To reduce the patient's burden, other methods such as capillary microsampling have been designed, in which a finger prick is sufficient for blood collection. This is way less invasive than venipuncture and enables patients to perform one or more finger pricks themselves. Furthermore, capillary microsampling offers the possibility to collect blood at home, resulting in fewer hospital visits, improving the patient experience, and reducing the threshold for blood sampling. In this study, we aim to validate the capillary microsampling method for olanzapine in comparison to the venipuncture method.

#### Study objective

Clinical validation of capillary microsampling with finger pricks for olanzapine. The validation method is performed in accordance with the EM guideline. In this process, the analytical methods are assessed for selectivity, carry-over, lower limit of quantification, calibration curve,

accuracy, precision, dilution, matrix effect, and stability

#### Study design

Cross-sectional observational study

#### Study burden and risks

Participating in this study will have negligible risk for the patients and during the study the participating patients will have no benefits. When the method is successfully validated, capillary capillary microsampling can be a great benefit to a larger group of patients that use drugs that require TDM.

## **Contacts**

#### **Public**

Maasstadziekenhuis

Maasstadweg 21 Rotterdam 3079 DZ NL

#### **Scientific**

Maasstadziekenhuis

Maasstadweg 21 Rotterdam 3079 DZ NL

# **Trial sites**

#### **Listed location countries**

**Netherlands** 

# **Eligibility criteria**

#### Age

Adults (18-64 years)

#### Inclusion criteria

- Age 18 to 64
- Treated with olanzapine
- Signed informed consent

#### **Exclusion criteria**

- Co-medication: lithium
- Unable to draw blood samples for study purposes
- If the clinician considers the patient to be mentally incompetent in decision making

# Study design

## **Design**

**Study type:** Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Other

#### Recruitment

NL

Recruitment status: Pending

Start date (anticipated): 01-11-2024

Enrollment: 40

Type: Anticipated

## Medical products/devices used

Generic name: Dried Blood Spot (DBS) testing

Registration: Yes - CE intended use

# **Ethics review**

Approved WMO

Date: 31-07-2024

Application type: First submission

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 12-02-2025

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

# **Study registrations**

# Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

# In other registers

Register ID

CCMO NL85836.000.24